---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114234"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:12:48.713244+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q3 net loss widens to $7.8M; raises $10.7M in October financing

## Summary
- Net loss Q3 2022: ($7.8M) or ($1.28)/share vs ($5.8M) ($0.97)/share in Q3 2021.
- Cash and equivalents $17.8M at Sep 30, 2022, down from $35.7M at Dec 31, 2021.
- Closed $10.7M gross proceeds from registered direct and private placement in October.
- R&D expense $5.4M (up from $3.9M) driven by Waldenstrom's macroglobulinemia pivotal trial.
- Awarded $2M NCI grant to expand Phase 1 pediatric brain tumor trial to Phase 1b.

## SEC filing metadata
- accession: 0001104659-22-114234
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/tm2229607d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114234
- JSON: https://secwatch.observer/filing/0001104659-22-114234.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114234.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported third quarter ended September 30, 2022 results: net income ($7.8) million, EPS ($1.28) per share.
  - Period: third quarter ended September 30, 2022
  - Net income: ($7.8) million
  - EPS: ($1.28) per share
  - Result: reported results
  source text: The net loss attributable to common stockholders for the quarter ended September 30, 2022 was ($7.8) million, or ($1.28) per share, compared to ($5.8) million, or ($0.97) per share, in the quarter ended September 30, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm
- Earnings Releases
  Cellectar Biosciences, Inc. reported nine months ended September 30, 2022 results: net income ($21.4) million, EPS ($3.50) per share.
  - Period: nine months ended September 30, 2022
  - Net income: ($21.4) million
  - EPS: ($3.50) per share
  - Result: reported results
  source text: the loss attributable to common stockholders for the nine months ended September 30, 2022 was ($21.4) million, or ($3.50) per share, compared to ($18.2) million, or ($3.39) per share, in 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.